Changes in weight secondary to improved odor perception in chronic rhinosinusitis with nasal polyps' patients treated with Dupilumab
- PMID: 39404880
- PMCID: PMC11735516
- DOI: 10.1007/s00405-024-09021-0
Changes in weight secondary to improved odor perception in chronic rhinosinusitis with nasal polyps' patients treated with Dupilumab
Abstract
Purpose: The advent of biologic therapies, notably Dupilumab, has transformed therapeutic approaches to nasal polyposis. This retrospective multicentric study aimed to investigate weight changes in CRSwNP patients undergoing Dupilumab treatment and explore potential correlations with olfactory improvement.
Methods: Ninety-six patients with CRSwNP were followed for at least 12 months, with assessments including BMI (Body Mass Index), olfactory function, and disease severity.
Results: Significant increases in BMI and olfactory perception were observed after 1 year of Dupilumab treatment (p < .001). Subgroup analysis showed that patients with hyposmia and normosmia at T12 (1-year follow up) experienced significant weight gain (p < .001) alongside improved olfaction (both p < .001). Conversely, patients with anosmia after 1 year of therapy and also patients with stable or worsened olfaction did not show significant BMI changes (respectively p = .201 and p = .107).
Conclusion: While these findings suggest a correlation between olfactory improvement and weight gain/BMI, factors like improved nasal airflow and corticosteroid cessation under Dupilumab treatment may also influence weight in CRPwNP patients. The study highlights the need for further research to elucidate the causal relationship and long-term implications of Dupilumab-induced olfactory improvement on weight regulation.
Keywords: BMI; Biologics; Chronic rhinosinusitis with nasal polyps; Dupilumab; Hyposmia; Olfaction.
© 2024. The Author(s).
Conflict of interest statement
Declaration. Conflicting Interests: Eugenio De Corso: Lecture fees and participations in experts board meeting of GSK, Novartis, Sanofi, Astrazeneca, Firma. Carlotta Pipolo: Lecture fees and participations in experts board meeting of GSK, Novartis, Sanofi, Astrazeneca, Firma and Deca. All other Authors declare that there is no conflict of interest.
Similar articles
-
Clinical effectiveness of dupilumab in CRSwNP: unaffected by baseline nasal polyp size in real-world settings.Eur Arch Otorhinolaryngol. 2025 Jun;282(6):3329-3334. doi: 10.1007/s00405-025-09275-2. Epub 2025 Feb 20. Eur Arch Otorhinolaryngol. 2025. PMID: 39979624 Free PMC article.
-
Dupilumab Treatment Is Associated With Clinical Improvement and a Shift Toward a Health-Associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis.Allergy. 2025 Jun;80(6):1746-1756. doi: 10.1111/all.16600. Epub 2025 Jun 2. Allergy. 2025. PMID: 40452334 Free PMC article.
-
Two-Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease.Allergy. 2025 Jun;80(6):1737-1745. doi: 10.1111/all.16579. Epub 2025 May 16. Allergy. 2025. PMID: 40377347 Free PMC article.
-
Systemic treatments for eczema: a network meta-analysis.Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD013206. doi: 10.1002/14651858.CD013206.pub2. Cochrane Database Syst Rev. 2020. PMID: 32927498 Free PMC article.
-
Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.Int Arch Allergy Immunol. 2022;183(3):279-288. doi: 10.1159/000519228. Epub 2021 Oct 4. Int Arch Allergy Immunol. 2022. PMID: 34607329
Cited by
-
The impact of olfactory loss on quality of life: a 2025 review.Chem Senses. 2025 Jan 22;50:bjaf023. doi: 10.1093/chemse/bjaf023. Chem Senses. 2025. PMID: 40719006 Free PMC article.
References
-
- Bachert C, Han JK, Wagenmann M et al (2021) EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol 147(1):29–36. 10.1016/J.JACI.2020.11.013 - PubMed
-
- Fokkens WJ, Lund VJ, Hopkins C et al (2020) European position paper on Rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl S29):1–464. 10.4193/RHIN20.600 - PubMed
-
- Mullol J, Bachert C, Amin N et al (2022) Olfactory outcomes with Dupilumab in Chronic Rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 10(4):1086–1095e5. 10.1016/J.JAIP.2021.09.037 - PubMed
-
- Chung JH, Lee YJ, Kang TW et al (2015) Altered quality of Life and Psychological Health (SCL-90-R) in patients with chronic Rhinosinusitis with nasal polyps. Ann Otol Rhinol Laryngol 124(8):663–670. 10.1177/0003489415576181 - PubMed